TrialCancer chemotherapy and pharmacology2024

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.

Arjun Mittra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.